OakChart

TuHURA Biosciences Inc

HURAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 11:36 AM ET

1.55+0.04 (2.65%)
2026-11-11 17:37 CET
Market cap
96.23 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-30.63 USD m
Free cash flow, TTM
-29.90 USD m
EPS diluted, TTM
-0.53
P/E
-
Compare

Price

HURA against its 20, 50 and 200-day averages
2050200beat
1.502.002.502.3M4.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HURAclose 1.5520-day 1.8350-day 1.95200-day 2.011.55

54.8% under the 52-week high of 3.43 on 15 Apr 2026. 52-week low 0.41 on 3 Feb 2026. Last 15 sessions, 48.7% high to low

Profile

HURA
52-week range, 38% of the way up
0.413.43

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded by Michael Lawman, Patricia Lawman and James A. Bianco on May 4, 2023 and is headquartered in Tampa, FL.

Employees22
IPOFeb 22, 2013
Beta-0.23
ATR, 14d0.15
Rel volume2.30
Short float14.89%
Insider own34.62%
Inst own15.09%

Snapshot

6 groups

Valuation

Index-
Market Cap98.78M
Enterprise Value102.07M
Income-30.63M
Sales0.00M
Book/sh0.29
Cash/sh0.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees22
IPOFeb 22, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B5.42
P/C98.78
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.18
Current Ratio0.18
Debt/Eq0.22
LT Debt/Eq0.20
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.53
EPS next Y-0.61
EPS next Q-0.14
EPS this Y11.75%
EPS next Y-9.35%
EPS next 5Y36.24%
EPS past 3/5Y87.54% 81.38%
Sales past 3/5Y- -
EPS Y/Y TTM84.80%
Sales Y/Y TTM-
EPS Q/Q32.55%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.8.68% -

Ownership

Insider Own34.62%
Insider Trans0.00%
Inst Own15.09%
Inst Trans-2.61%
ROA-92.29%
ROE-161.39%
ROIC-137.37%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-15.28%
SMA50-20.35%
SMA200-22.84%
Trades-

Technical

Shs Outstand63.68M
Shs Float41.66M
Short Float14.89%
Short Ratio19.79
Short Interest6.20M
52W High3.43 -54.81%
52W Low0.41 278.05%
Volatility8.80% 9.44%
ATR (14)0.15
RSI (14)37.52
Beta-0.23
Rel Volume2.30
Avg Volume313.52K
Volume258,619

Performance

Perf Week-9.88%
Perf Month-14.36%
Perf Quarter-32.61%
Perf Half Y-38.25%
Perf YTD104.84%
Perf Year-34.87%
Perf 3Y-88.44%
Perf 5Y-99.90%
Perf 10Y-100.00%
Recom1.00
Target Price7.87
Prev Close1.51
Price1.55
Change %2.65%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Apr 27, 2026InitiatedCCitizensMkt Outperform$9+480.6%
Mar 03, 2025InitiatedHH.C. WainwrightBuy$13+738.7%
Dec 19, 2024InitiatedRRodman & RenshawBuy$11+609.7%
Nov 05, 2024InitiatedMMaxim GroupBuy$15+867.7%

Peers

Mkt cap
TickerCompanyMkt cap
GNLXGenelux Corp88.99M
CADLCandel Therapeutics Inc725.40M
REPLReplimune Group Inc2.16B
PDSBPDS Biotechnology Corp107.09M
CUECue Biopharma Inc142.24M
ONCYOncolytics Biotech Inc50.31M
MAIAMAIA Biotechnology Inc64.53M
IOVAIovance Biotherapeutics Inc3.73B
CRVSCorvus Pharmaceuticals Inc976.81M
KZIAKazia Therapeutics Limited ADR87.10M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
  • TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma (PR Newswire) -6.42%
  • TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 (PR Newswire)
  • TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology (PR Newswire)
  • TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers (PR Newswire)
  • Loading…
  • TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
  • TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire) +7.39%
  • TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference (PR Newswire)
  • TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire) -7.97% +10.39%
  • TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference (PR Newswire)
  • TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 (PR Newswire)
  • TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations (PR Newswire)
  • TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (PR Newswire) -9.50%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.140-0.153-0.1400.000.003
2026Q12026-05-12-0.130-0.120-0.1300.000.003
2025Q42026-04-01-0.125-0.123-0.1230.00-3
2025Q32025-11-14-0.140-0.147-0.140--3
2025Q22025-08-14-0.210-0.140-0.214-0.003
2025Q12025-05-13-0.150-0.120-0.1540.000.003
2024Q42024-10-08-1.400--0.142---
2024Q32024-05-14-1.750--1.5810.00--
2024Q22024-02-14-8.400-4.900-8.272--1
2024Q12023-11-13-64.050-20.300-63.909--1
2023Q42023-09-18-60.550-36.925-69.028--2
2023Q32023-05-11-67.900-3.500-68.001--1
2023Q22023-02-14-73.500-110.25-73.6220.004.912
2023Q12022-11-09-122.50.000-118.560.004.711
2022Q42022-09-27-70.000-35.000-145.480.000.001
2022Q32022-05-13-192.5-186.67-190.860.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-5,530-2,581-5,525--
2020FY-1,523-1,037-1,5320.000.00
2021FY-2,800-2,464-2,8060.000.00
2022FY-910-735-903.04-0.00
2023FY-324.45-236.6-324.49--
2024FY-11.200--1.214--
2025FY-0.630-0.617-0.6300.000.00
2026FY--0.556--0.00
2027FY--0.608--16.92
2028FY--0.163--51.64
2029FY-0.900--157.76
2030FY-1.750--239.75

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-142000.000.000.00
2026Q3S2026-05-262000.000.000.00
2026Q3S2026-05-121000.000.000.00
2026Q3S2026-04-241000.000.000.00
2026Q3R2026-08-25200-0.13-0.14-0.12
2026Q3R2026-08-14100-0.14-0.14-0.14
2026Q3R2026-08-02100-0.14-0.14-0.14
2026Q3R2026-05-26200-0.15-0.15-0.14
2026Q3R2026-05-12100-0.15-0.15-0.15
2026Q3R2026-04-24100-0.15-0.15-0.15
2026Q3R2025-11-14100-0.12-0.12-0.12
2026Q3E2026-10-31501-0.14-0.15-0.12
2026Q3E2026-10-23502-0.14-0.15-0.12
2026Q3E2026-09-03401-0.14-0.14-0.12

Estimate history

EPS, annual-12950-9491.475-5524.995-1532.003-2805.845-903.035-324.485-1.214-0.627-0.5334
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.581-0.142-0.154-0.214-0.14-0.123-0.126-0.144
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly00000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0010.0010.0020.0070.0190.0370.04842.32459.33663.683
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.5842.32443.6849.91451.25559.33663.57963.683
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.070.120.060.060.060.030.010.02
Gross Profit-0.10-0.07-0.12-0.06-0.06-0.06-0.03-0.01-0.02
Selling, General and Administrative Excl. Other31.3228.0517.538.4014.7422.6221.548.138.38
Research and Development22.7820.4613.342.669.3115.1711.813.633.66
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-31.42-28.12-17.65-8.45-14.80-22.68-21.57-8.14-8.40
Interest Expense1.120.634.140.000.000.000.120.000.00
Unusual Expense-2.061.260.260.000.000.0016.591.05-0.43
Net Income Before Taxes-30.62-30.05-21.68-8.32-14.65-22.66-38.30-9.13-8.05
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-30.62-30.05-21.68-8.32-14.65-22.66-38.30-9.13-8.05
Net Income From Continuing Operations-30.62-30.05-21.68-8.32-14.65-22.66-38.30-9.13-8.05
Net Income-30.63-30.06-22.65-8.50-15.02-25.13-41.50-9.14-8.13
EPS (Recurring)-0.50-0.61-1.20-11.29-324.48-903.03-2,020.57-1,408.38-5,731.24
EPS (Basic, Before Extraordinaries)-0.53-0.63-1.21-11.29-324.48-903.03-2,805.84-1,532.00-5,524.99
EPS (Diluted)-0.53-0.63-1.21-11.29-324.48-903.03-2,805.84-1,532.00-5,524.99
EBITDA-31.32-28.05-17.53-8.40-14.74-22.62-21.54-8.13-8.38
Non-Operating Income (Expense)-0.15-0.050.360.130.150.02-0.010.07-0.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.536.421.960.611.492.255.280.490.43
Shares Outstanding63.6859.3442.321.580.050.040.020.010.00
Market Capitalization96.2396.23172.947.473.419.1137.163.941.69

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q5
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.020.020.020.010.010.020.03
Gross Profit-0.03-0.02-0.02-0.02-0.01-0.01-0.02-0.03
Selling, General and Administrative Excl. Other8.747.518.376.715.967.005.683.70
Research and Development6.595.216.034.954.914.583.982.95
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.76-7.53-8.39-6.73-5.98-7.02-5.69-3.73
Interest Expense0.470.030.610.02-0.000.522.00
Unusual Expense0.000.00-2.240.183.900.00-0.06-0.02
Net Income Before Taxes-9.22-7.54-6.76-7.10-9.52-6.66-6.00-5.58
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-9.22-7.54-6.76-7.10-9.52-6.66-6.00-5.58
Net Income From Continuing Operations-9.22-7.54-6.76-7.10-9.52-6.66-6.00-5.58
Net Income-9.23-7.54-6.76-7.10-9.53-6.67-6.00-6.54
EPS (Recurring)-0.14-0.13-0.15-0.14-0.15-0.15-0.14-3.01
EPS (Basic, Before Extraordinaries)-0.14-0.13-0.12-0.14-0.21-0.15-0.14-3.00
EPS (Diluted)-0.14-0.13-0.12-0.14-0.21-0.15-0.14-3.00
EBITDA-8.74-7.51-8.37-6.71-5.96-7.00-5.68-3.70
Non-Operating Income (Expense)0.010.020.00-0.180.350.350.160.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.142.802.151.451.411.421.080.27
Shares Outstanding63.6863.5859.3451.2549.9143.6842.322.18
Market Capitalization96.23108.6945.95124.1297.41136.58172.947.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments3.6218.654.911.5311.7810.542.393.725.97
Short Term Receivables0.500.220.000.000.000.000.000.030.04
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.500.740.621.741.481.260.360.281.03
Total Current Assets4.6219.615.533.2713.2611.792.764.037.05
Net Property, Plant & Equipment0.690.320.670.710.090.150.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets22.01-0.000.000.000.000.000.010.03
Other Assets0.030.030.000.002.601.600.180.000.00
Total Assets27.3519.976.203.9815.9513.542.944.047.07
Short Term Debt Incl. Current Port. of LT Debt0.400.160.000.000.000.000.000.000.00
Accounts Payable3.773.152.212.783.272.222.011.741.48
Other Current Liabilities1.752.020.050.300.720.560.660.330.16
Total Current Liabilities5.925.332.263.083.992.782.672.071.64
Long Term Debt0.300.040.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.20--------
Other Liabilities0.000.000.190.170.160.180.000.000.00
Total Liabilities6.425.372.443.254.152.962.672.071.64
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.280.2810.2510.6412.5514.934.804.986.43
Common Equity20.6514.32-6.50-9.91-0.76-4.35-4.54-3.01-0.99
Total Shareholders Equity20.9314.593.760.7311.7910.580.261.975.44
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity20.9314.593.760.7311.7910.580.261.975.44
Total Liabilities & Stockholders Equity27.3519.976.203.9815.9513.542.944.047.07
Book Value Per Share0.350.34-4.11-205.08-20.27-232.51-693.55-1,372.11-754.50
Tangible Book Value Per Share-0.020.34-4.11-205.08-20.27-232.51-693.55-1,377.61-776.15
Full-Time Employees221911172020191719
Price to Book Ratio5.28-0.99-1.72-0.34-12.00-8.54-0.87-0.356.34
Return on Assets-127.02-181.10-163.44-147.03-153.68-464.75-261.67-144.85-148.65
Return on Equity-169.18-282.97-370.77-233.90-202.55-706.33-818.28-217.44-185.43
Return on Invested Capital-141.51-148.14-221.45-2,003.97-192.12-361.95-3,469.96-409.05-204.93
Quick Ratio0.783.682.451.063.324.241.031.944.30
Current Ratio0.783.682.451.063.324.241.031.944.30

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-30.62-30.05-21.68-8.32-14.65-22.66-38.30-9.13-8.05
Depreciation0.100.070.120.060.060.060.030.010.02
Other Funds (Non Cash)7.905.503.550.804.922.2622.060.700.57
Funds from Operations-22.63-24.48-18.01-7.47-9.67-20.34-16.21-8.41-7.46
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-7.06-3.153.290.29-2.19-0.06-2.650.491.13
Cash from Operating Activities-29.69-27.63-14.73-7.18-11.87-20.39-18.86-7.93-6.33
Capital Expenditures-0.21-0.08-0.06-0.02-0.230.00-0.010.000.00
Net Assets From Acquisitions0.00-1.260.000.000.000.000.970.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.00-5.990.000.000.000.000.000.00
Purchase of Investments0.000.00-5.990.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.21-1.34-6.05-0.02-0.230.000.960.000.00
Cash Dividends Paid-0.01-0.010.00-0.01-0.01-0.01-0.01-0.01-0.01
Change in Capital Stock18.6020.376.7510.581.9021.6426.086.634.08
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock18.6020.376.7510.581.9021.6426.086.634.08
Proceedsfrom Stock Options18.6016.754.700.000.000.000.000.000.00
Issuance or Reduction of Debt, Net3.800.6227.450.000.000.000.000.000.00
Change in Long Term Debt3.400.0027.450.000.000.000.000.000.00
Issuance of Long Term Debt3.400.0027.450.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-1.05-4.430.00-0.040.00-0.03-0.030.00
Other Financing Activities Uses0.00-1.05-4.430.00-0.040.00-0.03-0.030.00
Cash from Financing Activities22.3919.9329.7710.571.8521.6426.046.604.07
Net Change in Cash-7.52-9.048.993.37-10.241.248.14-1.33-2.25
Free Cash Flow-29.90-27.71-14.79-7.20-12.10-20.39-18.87-7.93-6.33
Preferred Dividends (Cash Flow)--0.01--0.01-0.01-0.01-0.01-0.01-0.01
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments1.006.303.622.708.516.22
Short Term Receivables0.000.000.500.003.410.10
Inventories0.000.000.000.000.000.00
Other Current Assets0.660.680.500.810.628.01
Total Current Assets1.666.984.623.5012.5414.33
Net Property, Plant & Equipment0.750.680.690.380.270.31
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets22.0122.0122.0121.8221.820.00
Other Assets7.330.030.030.000.000.00
Total Assets31.7529.7027.3525.7034.6214.64
Short Term Debt Incl. Current Port. of LT Debt0.210.210.400.580.560.16
Accounts Payable3.083.953.774.133.653.08
Other Current Liabilities5.961.911.754.1310.971.53
Total Current Liabilities9.266.075.928.8315.174.78
Long Term Debt3.790.250.300.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.200.200.20---
Other Liabilities0.000.000.000.080.000.00
Total Liabilities13.256.516.428.9215.174.78
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.280.280.280.280.280.28
Common Equity18.2222.9120.6516.5019.179.58
Total Shareholders Equity18.5023.1920.9316.7819.459.86
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity18.5023.1920.9316.7819.459.86
Total Liabilities & Stockholders Equity31.7529.7027.3525.7034.6214.64
Book Value Per Share0.290.360.350.320.380.22
Tangible Book Value Per Share-0.060.01-0.02-0.10-0.050.22
Full-Time Employees--22---
Price to Book Ratio5.285.142.356.4610.17-0.79
Return on Assets-92.29-139.48-127.02-110.91-152.10-174.44
Return on Equity-161.39-187.16-169.18-418.06-287.92-244.16
Return on Invested Capital-41.37-32.15-31.84-42.33-48.97-67.61
Quick Ratio0.181.150.780.400.833.00
Current Ratio0.181.150.780.400.833.00

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-9.22-7.54-6.76-7.10-9.52-6.66
Depreciation0.030.020.020.020.010.01
Other Funds (Non Cash)2.442.800.721.951.411.42
Funds from Operations-6.76-4.72-6.02-5.14-8.10-5.23
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.880.300.46-5.951.860.49
Cash from Operating Activities-8.63-4.41-5.56-11.09-6.25-4.74
Capital Expenditures-0.14-0.05-0.030.00-0.01-0.04
Net Assets From Acquisitions0.000.000.000.00-1.260.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.001.11-1.11
Purchase of Investments0.000.000.000.001.11-1.11
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.14-0.05-0.030.00-0.16-1.15
Cash Dividends Paid-0.00-0.00-0.00-0.00-0.00-0.00
Preferred Dividends (Cash Flow)-0.00-0.00-0.00-0.00-0.00-0.00
Change in Capital Stock0.087.355.325.859.200.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.087.355.325.859.200.00
Proceedsfrom Stock Options0.087.355.325.856.08-0.50
Issuance or Reduction of Debt, Net3.39-0.211.19-0.580.000.00
Change in Long Term Debt3.400.000.000.000.000.00
Issuance of Long Term Debt3.400.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.50-0.55
Other Financing Activities Uses0.000.000.000.00-0.50-0.55
Cash from Financing Activities3.477.146.515.278.70-0.55
Net Change in Cash-5.302.680.92-5.822.29-6.44
Free Cash Flow-8.77-4.46-5.58-11.09-6.25-4.78

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.89%6.2M41.7M274.94K
2026-10-1514.25%5.9M41.7M227.31K
2026-09-3014.63%6.1M41.7M260.36K
2026-09-1515.07%6.3M41.7M389.49K
2026-08-3115.05%6.3M41.7M434.31K
2026-08-1415.18%6.3M41.7M493.71K
2026-07-3115.63%6.5M41.6M537.76K
2026-07-1515.97%6.6M41.6M697.53K
2026-06-3016.80%7.0M41.6M903.53K
2026-06-1518.65%7.8M41.6M854.59K
2026-05-2920.30%8.4M41.6M924.06K
2026-05-1516.40%8.0M48.7M1.03M
2026-04-3017.22%8.3M48.0M2.01M
2026-04-1517.37%8.3M47.9M1.90M
2026-03-3115.63%7.5M47.9M1.65M
2026-03-1315.74%7.2M45.7M1.62M
2026-02-2715.23%7.0M45.7M1.57M
2026-02-1316.58%7.6M45.7M1.41M
2026-01-307.06%3.2M45.7M365.39K
2026-01-156.54%3.0M45.7M348.23K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-068-KCurrent report2026-11-02SEC
2026-10-168-KCurrent report2026-10-09SEC
2026-09-248-KCurrent report2026-09-21SEC
2026-09-178-KCurrent report2026-09-14SEC
2026-09-178-K/A2026-09-10SEC
2026-09-168-KCurrent report2026-09-10SEC
2026-09-048-KCurrent report2026-09-02SEC
2026-08-28SCHEDULE 13D/ASEC
2026-08-218-KCurrent report2026-08-20SEC
2026-08-198-KCurrent report2026-08-18SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-138-KCurrent report2026-08-07SEC
2026-07-298-KCurrent report2026-07-28SEC
2026-07-09ARSAnnual report to security holders. 2025-12-31SEC
2026-07-09DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-09DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-18SEC
2026-07-078-KCurrent report2026-06-30SEC
2026-06-26PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-18SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-05-298-KCurrent report2026-05-26SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-04-308-K/A2026-04-02SEC
2026-04-3010-K/A2025-12-31SEC
2026-04-228-KCurrent report2026-04-21SEC
2026-04-08424B5SEC
2026-04-088-KCurrent report2026-04-02SEC
2026-04-018-KCurrent report2026-04-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.56%
NORTHERN TRUST CORP2.55%
BlackRock, Inc.1.08%
FIFTH THIRD BANCORP0.82%
GEODE CAPITAL MANAGEMENT, LLC0.74%
MILLENNIUM MANAGEMENT LLC0.71%
AQR CAPITAL MANAGEMENT LLC0.67%
VANGUARD FIDUCIARY TRUST CO0.39%
CITADEL ADVISORS LLC0.36%
STATE STREET CORP0.30%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.73%
VANGUARD EXTENDED MARKET INDEX FUND0.70%
Fidelity Small Cap Index Fund0.67%
VANGUARD RUSSELL 2000 INDEX FUND0.34%
Fidelity Extended Market Index Fund0.33%
iShares Micro-Cap ETF0.26%
Schwab Small-Cap Index Fund0.16%
Fidelity Total Market Index Fund0.12%
Fidelity Series Total Market Index Fund0.10%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND0.06%

OakChart. HURA. Cached 15 minutes.

Some panels did not load: insider.